Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to TradeZacks Investment Research • 11/16/22
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's DiseasePRNewsWire • 10/11/22
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's DiseasePRNewsWire • 10/06/22
Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A LookSeeking Alpha • 10/06/22
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion DiseasesPRNewsWire • 09/13/22
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's DiseasePRNewsWire • 08/24/22
Annovis Bio to Participate on Alzheimer's Association International Conference PanelPRNewsWire • 08/01/22
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's DiseasePRNewsWire • 07/07/22
Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by InfectionsPRNewsWire • 06/09/22
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate UpdateNewsfile Corp • 05/04/22
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on AgingNewsfile Corp • 04/28/22
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating DiseaseNewsfile Corp • 04/11/22
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-VestNewsfile Corp • 03/23/22